Top

Journal of Neurology

Published in:

14-06-2023 | Direct Oral Anticoagulant | Review

Safety and efficacy of intravenous thrombolysis in patients with acute ischemic stroke taking direct oral anticoagulants prior to stroke: a meta-analysis

Authors: Huo Liang, Xue Wang, Xuemei Quan, Bin Qin, Jian Zhang, Shuolin Liang, Zhijian Liang

Published in: Journal of Neurology | Issue 9/2023

Abstract

Background

To assess the safety and efficacy of intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS) taking direct oral anticoagulants (DOACs) prior to stroke.

Methods

Literature was searched in PubMed, Cochrane Library, and Embase until March 13, 2023. The primary outcome was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included excellent outcome (modified Rankin Scale [mRS] 0–1), functional independence (mRS 0–2), and mortality. Odds ratios (OR) with 95% confidence intervals (CI) were estimated using a random-effects model.

Results

Five non-randomized studies included 239,879 patients with AIS treated with IVT, with 3400 (1.42%) taking DOACs prior to stroke. The rates of sICH did not differ statistically between patients taking DOACs and those not taking anticoagulants (unadjusted OR 0.98; 95% CI 0.67–1.44; P = 0.92; adjusted OR 0.81; 95% CI 0.64–1.03; P = 0.09). Patients taking DOACs had significantly higher adjusted rates of excellent outcome (adjusted OR 1.22; 95% CI 1.06–1.40; P < 0.01) and functional independence (adjusted OR 1.25; 95% CI 1.10–1.42; P < 0.01) at discharge than those not taking anticoagulants. No significant difference was observed in mortality and other efficacy outcomes between groups after adjustment.

Conclusion

The meta-analysis indicated that taking DOACs prior to stroke does not significantly increase the risk of sICH in selected patients with AIS treated with IVT. Furthermore, the benefits of IVT in selected patients taking DOACs appear to be comparable to those not taking anticoagulants. Further research is warranted to confirm the findings.

Available only for authorised users

January CT, Wann LS, Calkins H et al (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 74:104–132. https://doi.org/10.1016/j.jacc.2019.01.011CrossRefPubMed

Meinel TR, Frey S, Arnold M et al (2019) Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants: a systematic review. PLoS One 14:e0213379. https://doi.org/10.1371/journal.pone.0213379CrossRefPubMedPubMedCentral

Seiffge DJ, De Marchis GM, Koga M et al (2020) Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. Ann Neurol 87:677–687. https://doi.org/10.1002/ana.25700CrossRefPubMedPubMedCentral

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587. https://doi.org/10.1056/NEJM199512143332401

Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329. https://doi.org/10.1056/NEJMoa0804656CrossRefPubMed

Lees KR, Emberson J, Blackwell L et al (2016) Effects of Alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke 47:2373–2379. https://doi.org/10.1161/STROKEAHA.116.013644CrossRefPubMedPubMedCentral

Emberson J, Lees KR, Lyden P et al (2014) Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 384:1929–1935. https://doi.org/10.1016/S0140-6736(14)60584-5CrossRefPubMedPubMedCentral

Powers WJ, Rabinstein AA, Ackerson T et al (2019) Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 50:e344–e418. https://doi.org/10.1161/STR.0000000000000211CrossRefPubMed

Berge E, Whiteley W, Audebert H et al (2021) European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 6:I–LXII. https://doi.org/10.1177/2396987321989865CrossRefPubMedPubMedCentral

10.

Chao Y-T, Hu C-J, Chan L (2019) Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation: a case report. Medicine (Baltimore) 98:e14560. https://doi.org/10.1097/MD.0000000000014560CrossRefPubMed

11.

Ishihara H, Torii H, Imoto H et al (2014) Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. J Stroke Cerebrovasc Dis 23:e457–e459. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.07.008CrossRefPubMed

12.

Fluri F, Heinen F, Kleinschnitz C (2013) Intravenous thrombolysis in a stroke patient receiving rivaroxaban. Cerebrovasc Dis Extra 3:153–155. https://doi.org/10.1159/000355839CrossRefPubMedPubMedCentral

13.

Landais A, Ginoux C (2015) Intravenous thrombolysis for acute ischemic stroke in a patient receiving rivaroxaban. J Stroke Cerebrovasc Dis 24:e73-74. https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.10.014CrossRefPubMed

14.

Korya D, Dababneh H, Moussavi M et al (2014) Intravenous thrombolysis in a patient using factor Xa inhibitor. J Vasc Interv Neurol 7:1–4PubMedPubMedCentral

15.

Rota E, Bruzzone G, Agosti S et al (2017) A case report of parenchymal hematoma after intravenous thrombolysis in a rivaroxaban-treated patient. Medicine (Baltimore) 96:e9435. https://doi.org/10.1097/MD.0000000000009435CrossRefPubMed

16.

Anan C, Oomura M, Saeki T et al (2015) Fatal intraperitoneal bleeding after intravenous administration of tissue plasminogen activator. J Stroke Cerebrovasc Dis 24:e177-178. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.03.025CrossRefPubMed

17.

Meinel TR, Wilson D, Gensicke H et al (2023) Intravenous thrombolysis in patients with ischemic stroke and recent ingestion of direct oral anticoagulants. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2022.4782CrossRefPubMedPubMedCentral

18.

Okada T, Yoshimoto T, Wada S et al (2022) Intravenous thrombolysis with Alteplase at 0.6 mg/kg in patients with ischemic stroke taking direct oral anticoagulants. J Am Heart Assoc 11:e025809. https://doi.org/10.1161/JAHA.122.025809CrossRefPubMedPubMedCentral

19.

Kam W, Holmes DN, Hernandez AF et al (2022) Association of recent use of non-vitamin K antagonist oral anticoagulants with intracranial hemorrhage among patients with acute ischemic stroke treated with Alteplase. JAMA 327:760–771. https://doi.org/10.1001/jama.2022.0948CrossRefPubMed

20.

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

21.

Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

22.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Chapter 10: analysing data and undertaking meta-analyses. https://training.cochrane.org/handbook/current/chapter-10. Accessed 13 Oct 2022

23.

Xian Y, Federspiel JJ, Hernandez AF et al (2017) Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non-vitamin K Antagonist oral anticoagulants before stroke. Circulation 135:1024–1035. https://doi.org/10.1161/CIRCULATIONAHA.116.023940CrossRefPubMed

24.

Matute M-C, Masjuan J, Egido J-A et al (2012) Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis 33:231–239. https://doi.org/10.1159/000334662CrossRefPubMed

25.

Toyoda K, Yamagami H, Koga M (2018) Consensus guides on stroke thrombolysis for anticoagulated patients from japan: application to other populations. J Stroke 20:321–331. https://doi.org/10.5853/jos.2018.01788CrossRefPubMedPubMedCentral

26.

Zhang Y, Tang H, Gui X et al (2022) Safety of recanalization therapy in acute ischemic stroke patients on direct oral anticoagulant therapy: an updated systematic review and meta-analysis. Ann Indian Acad Neurol 25:1036–1046. https://doi.org/10.4103/aian.aian_271_22CrossRefPubMedPubMedCentral

27.

Shahjouei S, Tsivgoulis G, Goyal N et al (2020) Safety of intravenous thrombolysis among patients taking direct oral anticoagulants. Stroke 51:533–541. https://doi.org/10.1161/STROKEAHA.119.026426CrossRefPubMed

28.

Liu M, Zheng Y, Li G (2018) Safety of recanalization therapy in patients with acute ischemic stroke under anticoagulation: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 27:2296–2305. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.04.012CrossRefPubMed

29.

Machida T, Dohgu S, Takata F et al (2017) Role of thrombin-PAR1-PKCθ/δ axis in brain pericytes in thrombin-induced MMP-9 production and blood-brain barrier dysfunction in vitro. Neuroscience 350:146–157. https://doi.org/10.1016/j.neuroscience.2017.03.026CrossRefPubMed

30.

Zhang Y, Wang Y, Zuo Z et al (2014) Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke. J Neurol Sci 347:148–154. https://doi.org/10.1016/j.jns.2014.09.036CrossRefPubMed

31.

Bieber M, Foerster KI, Haefeli WE et al (2021) Treatment with edoxaban attenuates acute stroke severity in mice by reducing blood-brain barrier damage and inflammation. Int J Mol Sci 22:9893. https://doi.org/10.3390/ijms22189893CrossRefPubMedPubMedCentral

32.

Sun L, Zhou W, Ploen R et al (2013) Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 110:153–161. https://doi.org/10.1160/TH12-12-0942CrossRefPubMed

33.

Ploen R, Sun L, Zhou W et al (2014) Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke. J Cereb Blood Flow Metab 34:495–501. https://doi.org/10.1038/jcbfm.2013.226CrossRefPubMed

34.

Pfeilschifter W, Bohmann F, Baumgarten P et al (2012) Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol 71:624–633. https://doi.org/10.1002/ana.23558CrossRefPubMed

35.

Sakamoto Y, Okubo S, Sekine T et al (2018) Prior direct oral anticoagulant therapy is related to small infarct volume and no major artery occlusion in patients with stroke and non-valvular atrial fibrillation. J Am Heart Assoc 7:e009507. https://doi.org/10.1161/JAHA.118.009507CrossRefPubMedPubMedCentral

36.

Barreto A, Ford G, Shen L et al (2017) Randomized, multicenter trial of ARTSS-2 (Argatroban with recombinant tissue plasminogen activator for acute stroke). Stroke 48:1608–1616. https://doi.org/10.1161/STROKEAHA.117.016720CrossRefPubMedPubMedCentral

37.

Chen H-S, Cui Y, Zhou Z-H et al (2023) Effect of Argatroban plus intravenous Alteplase vs intravenous Alteplase alone on neurologic function in patients with acute ischemic Stroke: the ARAIS randomized clinical trial. JAMA 329:640–650. https://doi.org/10.1001/jama.2023.0550CrossRefPubMedPubMedCentral

38.

Wahlgren N, Ahmed N, Eriksson N et al (2008) Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe implementation of thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 39:3316–3322. https://doi.org/10.1161/STROKEAHA.107.510768CrossRefPubMed

39.

Fuentes B, Castillo J, San José B et al (2009) The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study. Stroke 40:562–568. https://doi.org/10.1161/STROKEAHA.108.519926CrossRefPubMed

40.

Hacke W, Donnan G, Fieschi C et al (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768–774. https://doi.org/10.1016/S0140-6736(04)15692-4CrossRefPubMed

41.

Rabinstein AA, Albers GW, Brinjikji W, Koch S (2019) Factors that may contribute to poor outcome despite good reperfusion after acute endovascular stroke therapy. Int J Stroke 14:23–31. https://doi.org/10.1177/1747493018799979CrossRefPubMed

42.

Zhang Y-H, Shi M-C, Wang Z-X et al (2021) Factors associated with poor outcomes in patients undergoing endovascular therapy for acute ischemic stroke due to large-vessel occlusion in acute anterior circulation: a retrospective study. World Neurosurg 149:e128–e134. https://doi.org/10.1016/j.wneu.2021.02.064CrossRefPubMed

Title: Safety and efficacy of intravenous thrombolysis in patients with acute ischemic stroke taking direct oral anticoagulants prior to stroke: a meta-analysis
Authors: Huo Liang
Xue Wang
Xuemei Quan
Bin Qin
Jian Zhang
Shuolin Liang
Zhijian Liang
Publication date: 14-06-2023
Publisher: Springer Berlin Heidelberg
Keywords: Direct Oral Anticoagulant
Direct Oral Anticoagulant
Stroke
Anticoagulant
Published in: Journal of Neurology / Issue 9/2023
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11815-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Safety and efficacy of intravenous thrombolysis in patients with acute ischemic stroke taking direct oral anticoagulants prior to stroke: a meta-analysis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2023

The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis

Analysis and hierarchical clustering of infratentorial morphological MRI identifies SCAs phenogroups

Correction to: Encephalitis in HIV‑infected adults in the antiretroviral therapy era

Association between peripheral adaptive immune markers and disease progression in Parkinson's disease

Oculomotor abnormalities indicate early executive dysfunction in prodromal X-linked dystonia-parkinsonism (XDP)

Morphological and molecular comparison of HIV-associated and sporadic inclusion body myositis